Literature DB >> 10071398

The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study.

P C Hannaford1, C R Kay.   

Abstract

BACKGROUND: So far, no-one has attempted to evaluate the overall balance of serious, but not necessarily fatal, disease among a cohort of oral contraceptive users. AIM: To emprirically assess the balance of risk of serious illness among a cohort of oral contraceptive users followed up for up to 28 years.
METHODS: Oral contraceptive-associated serious disease was defined as that which is often life-threatening and/or associated with long-term disability, and which has been found, or postulated, to be associated with use of combined oral contraceptives. Data from the Royal College of General Practitioners' (RCGP) Oral Contraception Study were examined to determine the rate of such conditions during 335,181 woman-years of observation in 'ever users' and 228,727 woman-years in 'never users'. The rates were standardized for age, parity, social class, and smoking.
RESULTS: Compared with never users, ever users had a small increased risk of any serious disease (relative risk = 1.17; 95% confidence interval = 1.09-1.25). Ever users had an excess risk of cerebrovascular disease, pulmonary embolism, and venous thromboembolism, and reduced risk of ovarian and endometrial cancer. The increased risk was seen only in younger women; by the age of 50, ever users had the same risk as never users. The risk appeared to be confined to women using older oral contraceptives containing 50 micrograms or more of oestrogen.
CONCLUSIONS: Past users of older, higher dose oral contraceptives can be reassured that the small increased risk of serious disease seen during current use does not persist after stopping, and that latent effects do not appear later in life. Currently available oral contraceptives, containing less than 50 micrograms of oestrogen accompanied by the progestogen, levonorgestrel, or norethisterone acetate, do not appear to be associated with an increased net risk of serious disease.

Entities:  

Keywords:  Biology; Cohort Analysis; Contraception; Contraceptive Methods; Developed Countries; Diseases; Europe; Family Planning; Follow-up Studies; Northern Europe; Oral Contraceptives; Research Methodology; Research Report; Risk Factors; Studies; United Kingdom; Vascular Diseases--women; Women

Mesh:

Substances:

Year:  1998        PMID: 10071398      PMCID: PMC1313240     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  9 in total

1.  Mortality associated with the control of fertility.

Authors:  C Tietze; J Bongaarts; B Schearer
Journal:  Fam Plann Perspect       Date:  1976 Jan-Feb

2.  Long-term benefits and risks of alternative methods of fertility control in the United States.

Authors:  I Kawachi; G A Colditz; S Hankinson
Journal:  Contraception       Date:  1994-07       Impact factor: 3.375

3.  Comparing the health risks and benefits of contraceptive choices.

Authors:  K Kost; J D Forrest; S Harlap
Journal:  Fam Plann Perspect       Date:  1991 Mar-Apr

4.  Mortality among oral contraceptive users: 20 year follow up of women in a cohort study.

Authors:  M P Vessey; L Villard-Mackintosh; K McPherson; D Yeates
Journal:  BMJ       Date:  1989-12-16

5.  Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.

Authors:  K W Bloemenkamp; F R Rosendaal; F M Helmerhorst; H R Büller; J P Vandenbroucke
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

6.  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

Authors:  H Jick; S S Jick; V Gurewich; M W Myers; C Vasilakis
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

7.  Oral contraceptive use and mortality during 12 years of follow-up: the Nurses' Health Study.

Authors:  G A Colditz
Journal:  Ann Intern Med       Date:  1994-05-15       Impact factor: 25.391

8.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.

Authors:  W O Spitzer; M A Lewis; L A Heinemann; M Thorogood; K D MacRae
Journal:  BMJ       Date:  1996-01-13
  9 in total
  2 in total

1.  Evaluating primary care groups.

Authors:  S Gillam; A Coulter
Journal:  Br J Gen Pract       Date:  1998-10       Impact factor: 5.386

2.  Medication use and risk of amyotrophic lateral sclerosis-a systematic review.

Authors:  Can Cui; Jiangwei Sun; Kyla A McKay; Caroline Ingre; Fang Fang
Journal:  BMC Med       Date:  2022-08-05       Impact factor: 11.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.